75 research outputs found

    A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    Get PDF

    Subcapsular liver biloma complicating cholecystectomy after cholecystoduodenal fistula: CT findings. Case study

    No full text
    The computed tomographic (CT) appearance and differential diagnosis of a large subcapsular liver biloma is described. The lesion complicated an open operation for cholecystoduodenal fistula and its development distal to the site of surgery is rare. Its recognition is important for treatment planning and selection of extraperitoneal approach when surgery is contemplated

    Combined anterior and posterior shoulder dislocation as a manifestation of a brain tumour

    No full text
    Seizures are sometimes the first manifestation of a brain tumour. They may give rise to shoulder fractures or fracture-dislocations. When bilateral, these lesions tend to be symmetrical. The patient reported here suffered from a previously undiagnosed brain tumour, the first manifestation of which were seizures, which provoked a bilateral shoulder dislocation in opposite directions. The posterior dislocation was recognized with a delay of 16 days. After an episode of seizures, shoulder dislocation can occur in either direction, and bilateral shoulder dislocations may not be symmetrical

    Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1α\alpha) in Waldenstr{\"o}m macroglobulinaemia

    No full text
    Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 alpha) and bone remodelling markers were evaluated in 38 patients with Waldenstrom macroglobulinaemia (WM) and correlated with clinical and laboratory variables. MIP-1 alpha was elevated in WM; untreated patients had higher MIP-1 alpha levels than patients in remission or with active disease after treatment. MIP-1 alpha correlated with increased bone resorption, beta(2)-microglobulin and splenomegaly. Receptor activator of nuclear factor-kappa B ligand serum levels were elevated in WM patients; the subsequent increased bone resorption was balanced by a comparable elevation of osteoprotegerin production and bone formation. These findings may explain the absence of lytic lesions in WM patients and suggest a potential role of MIP-1 alpha in WM

    Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in Waldenstrom macroglobulinaemia

    No full text
    Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 alpha) and bone remodelling markers were evaluated in 38 patients with Waldenstrom macroglobulinaemia (WM) and correlated with clinical and laboratory variables. MIP-1 alpha was elevated in WM; untreated patients had higher MIP-1 alpha levels than patients in remission or with active disease after treatment. MIP-1 alpha correlated with increased bone resorption, beta(2)-microglobulin and splenomegaly. Receptor activator of nuclear factor-kappa B ligand serum levels were elevated in WM patients; the subsequent increased bone resorption was balanced by a comparable elevation of osteoprotegerin production and bone formation. These findings may explain the absence of lytic lesions in WM patients and suggest a potential role of MIP-1 alpha in WM
    corecore